Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MDG1k | Xetra | EUR | Delayed | |
MDG1k | TradeGate | EUR | Delayed | |
MDG1k | Frankfurt | EUR | Delayed | |
MDG2 | Vienna | EUR | Real-time |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company has research collaboration with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
Name | Age | Since | Title |
---|---|---|---|
Frank Mathias | 59 | 2008 | Independent Member of the Supervisory Board |
Antoinette Hiebeler-Hasner | 63 | 2016 | Independent Deputy Chairwomen of the Supervisory Board |
Freda Stevenson | - | 2017 | Member of Scientific Advisory Board |
Anthony Man | 67 | 2020 | Independent Member of the Supervisory Board |
Micha Drukker | - | 2017 | Member of Scientific Advisory Board |
Peter H. Krammer | 56 | 2017 | Member of Scientific Advisory Board |
Jolanda de Vries | - | 2017 | Member of Scientific Advisory Board |
Lawrence E. Samelson | - | 2017 | Member of Scientific Advisory Board |
Ronald Scott | 67 | 2017 | Independent Member of the Supervisory Board |
Ernst-Ludwig Winnacker | 81 | 2016 | Co-Founder & Chairman Scientific Advisory Board |
Gerd Zettlmeissl | 68 | 2017 | Independent Chairman of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review